Harvoni

DRUG5 trials

Sponsors

University of California, San Francisco, Gilead Sciences, University of Nebraska, Icahn School of Medicine at Mount Sinai, Wake Forest University Health Sciences

Conditions

CirrhosisCryoglobulinemiaGenotype 1 Hepatitis C VirusHIVHepatitis CPorphyria Cutanea Tarda

Phase 2

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

CompletedNCT02825212

Icahn School of Medicine at Mount SinaiCryoglobulinemia, Hepatitis C

Start: 2016-02-29End: 2019-07-19Updated: 2020-12-17

Harvoni Treatment Porphyria Cutanea Tarda

CompletedNCT03118674

Wake Forest University Health SciencesHepatitis C, Porphyria Cutanea Tarda

Start: 2017-09-06End: 2022-03-04Updated: 2023-07-03

Phase 4

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

CompletedNCT02533934

University of California, San FranciscoCirrhosis, Hepatitis C, HIV

Start: 2016-08-31End: 2019-12-31Updated: 2021-02-02

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

CompletedNCT02759861

University of NebraskaGenotype 1 Hepatitis C Virus

Start: 2016-08-01End: 2020-10-01Updated: 2023-12-29

Unknown Phase

Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

CompletedNCT02591277

Gilead SciencesHepatitis C

Start: 2015-11-30End: 2017-11-01Updated: 2019-02-06

Related Papers

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.

2023-02-225 citations